Tau Immunotherapy Mechanisms

Tau Immunotherapy Mechanisms

Overview

Tau immunotherapy represents a promising therapeutic approach for Alzheimer's disease and other tauopathies. Anti-tau antibodies can clear pathological tau through multiple complementary mechanisms, including extracellular clearance, Fc receptor-mediated uptake, and intracellular clearance via TRIM21[@tau][@trimmediated2024]. Understanding these mechanisms is critical for optimizing antibody design and patient selection.

Pathway Diagram

Tau Immunotherapy Mechanisms

Overview

Tau immunotherapy represents a promising therapeutic approach for Alzheimer's disease and other tauopathies. Anti-tau antibodies can clear pathological tau through multiple complementary mechanisms, including extracellular clearance, Fc receptor-mediated uptake, and intracellular clearance via TRIM21[@tau][@trimmediated2024]. Understanding these mechanisms is critical for optimizing antibody design and patient selection.

Pathway Diagram

Mechanisms of Tau Clearance

1. Extracellular Tau Neutralization

Tau protein is released from neurons into the extracellular space through various mechanisms[@tau]:

• Synaptic Activity: Tau is released during normal synaptic transmission
• Exosome Secretion: Tau is packaged into extracellular vesicles
• Membrane Permeability: Pathological tau can leak through damaged membranes
• Necrotic Cell Death: Tau released from dying neurons

Key Benefits:

• Prevents tau propagation to downstream brain regions
• Neutralizes toxic extracellular tau species
• Reduces seeding activity

2. Fc Receptor (FcR) Mediated Clearance

Once bound to tau, antibodies can be cleared through Fc receptor-mediated phagocytosis[@tau][@trimmediated2024]:

• Microglial Uptake: Brain immune cells (microglia) express Fc gamma receptors
• Antibody-Tau Complex Recognition: Fc domains are recognized by Fcγ receptors
• Phagocytosis: Microglia engulf the antibody-tau complex
• Lysosomal Degradation: Tau is degraded within microglial lysosomes

3. Intracellular Clearance via TRIM21

TRIM21 is a cytosolic antibody receptor that provides a powerful intracellular clearance mechanism[@trimmediated2024][@igg]:

• Mechanism: Antibody entering cells binds to TRIM21
• Proteasomal Degradation: The antibody-TRIM21 complex targets tau for proteasomal degradation
• E3 Ligase Activity: TRIM21 acts as an E3 ubiquitin ligase
• Importance for IgG1: This mechanism is particularly important for IgG1 antibodies

• IgG1: Strong effector function, effective FcR uptake and TRIM21 clearance
• IgG4: Weaker effector function, primarily relies on extracellular neutralization

IgG Subclass Considerations

The choice of IgG subclass significantly impacts therapeutic efficacy[@trimmediated2024][@igg]:

| IgG Subclass | FcR Binding | TRIM21 Activity | Clinical Experience |
|--------------|-------------|-----------------|---------------------|
| IgG1 | Strong | High | E2814, JNJ-63733657 |
| IgG4 | Weak | Low | Semorinemab, Bepranemab |

Why IgG1 May Be Superior

However, IgG4 may offer advantages in safety profile due to reduced effector functions.

Target Epitope Considerations

The epitope targeted by the antibody influences mechanism of action[@tau]:

N-Terminal Targeting

• Targets tau before it becomes pathological
• May neutralize "early" tau species
• Limitation: May not effectively clear established pathology

Mid-Domain (MTBR) Targeting

• Targets pathologically phosphorylated regions
• Binds to tau within filaments
• Advantage: Can clear established pathology

C-Terminal Targeting

• Targets the microtubule-binding region
• Binds to aggregated tau species
• Advantage: Direct clearance of filaments

Clinical Implications

Understanding these mechanisms has important clinical implications:

Failed Programs and Lessons Learned

Several anti-tau antibody programs have failed in clinical trials[@gosuranemab][@taua]:

N-Terminal Antibodies - Failed

• Gosuranemab (BIIB092): N-terminal targeting, failed in TANGO trial
• Tilavonemab: N-terminal targeting, failed in Phase II
• Semorinemab: N-terminal targeting, mixed results in TAURIEL/LAURIET

Lessons Learned

Current Promising Programs

Based on mechanism considerations, the most promising programs include:

| Drug | Company | Target | IgG Subclass | Status |
|------|---------|--------|--------------|--------|
| E2814 | Eisai | MTBR | IgG1 | Phase III |
| Bepranemab | UCB | MTBR | IgG4 | Phase II |
| PRX005 | Prothena | MTBR | IgG1 | Phase I |

Extracellular vs Intracellular Tau Targeting

A critical distinction in anti-tau antibody design is whether the antibody targets tau in the extracellular space or within neurons. This distinction fundamentally shapes the therapeutic mechanism and efficacy[@tanglederivative2024].

Extracellular Tau Targeting (Passive Antibody Approach)

Most anti-tau antibodies in development target extracellular tau species:

Rationale:

• Tau is released from neurons via synaptic activity, exosomes, and necrotic cell death
• Extracellular tau serves as a "seed" for propagation to connected neurons
• Antibodies in the bloodstream can access extracellular tau in the brain interstitial fluid

Limitations:

• Does not directly clear intracellular tau pathology
• Requires sufficient antibody brain penetration
• May be too late in disease course when significant intracellular pathology exists

Intracellular Tau Targeting

Strategies to target intracellular tau include:

1. Antibody-Dependent Intracellular Delivery:

• antibodies engineered to enter neurons (e.g., using transportan peptides)
• bispecific antibodies that bind both tau and neuronal uptake receptors

• TRIM21 is a cytosolic Fc receptor that binds antibody-bound antigens
• When anti-tau antibodies enter cells (via endocytosis or penetration), they can be routed to TRIM21
• The TRIM21-antibody-tau complex is ubiquitinated and degraded by the proteasome
• This mechanism is particularly effective with IgG1 antibodies[@trimmediated2024]

• Antisense oligonucleotides (ASOs) reduce intracellular tau by decreasing MAPT mRNA
• BIIB080 (MAPTRx) reduces CSF tau by 50-60% via this mechanism

Comparison of Targeting Strategies

| Strategy | Target Location | Clearance Mechanism | Advantages | Limitations |
|----------|-----------------|---------------------|------------|-------------|
| Passive mAb (N-terminal) | Extracellular | FcR phagocytosis | Safe, well-tolerated | Limited efficacy |
| Passive mAb (MTBR) | Extracellular/ filament | FcR + direct binding | Can bind filaments | May miss intracellular |
| IgG1 mAb | Extracellular + intracellular | TRIM21 proteasomal | Enhanced clearance | Potential toxicity |
| ASO | Intracellular (mRNA) | Reduced synthesis | Direct target | Invasive delivery |

Epitope-Specific Mechanisms

N-Terminal Targeting (Failed Programs)

N-terminal antibodies target the first ~150 amino acids of tau:

Examples:

• Gosuranemab (BIIB092): Failed in TANGO trial (PSP)
• Tilavonemab (ABBV-8E12): Failed in Phase II (PSP)
• Semorinemab (RG6100): Mixed results (TAURIEL failed, LAURIET positive)

• N-terminal tau is released early in the pathological process
• Targeting early tau species could prevent propagation

• N-terminal antibodies may miss established intracellular pathology
• Disease progression may be too advanced by the time treatment begins
• N-terminal epitopes may not be accessible in aggregated filaments

Mid-Domain/MTBR Targeting (Promising)

The microtubule-binding repeat (MTBR, aa 244-368) is the core of tau fibrils:

Examples:

• E2814 (Eisai): Phase III, binds p-tau396/404
• Bepranemab (UCB): Phase II, binds aa 235-250
• PRX005 (Prothena): Phase I, binds MTBR

• MTBR is the aggregation core — targeting it directly blocks filament formation
• Antibodies can bind tau within filaments
• May clear established pathology more effectively

Conformational/C-Terminal Targeting

MC1 Epitope:

• MC1 is a conformational epitope (aa 312-322) specific to pathological tau
• Zagotenemab (LY3303563) targeted MC1 — failed in Phase II
• The conformational nature may limit antibody binding in vivo

Fc Engineering and Affinity Maturation

Modern anti-tau antibodies employ sophisticated Fc engineering:

Fc Region Optimization

IgG1 vs IgG4:

• IgG1: High FcR binding, complement activation, TRIM21 activity
• IgG4: Low effector functions, longer half-life, reduced ARIA risk

• Fc mutations to enhance or reduce effector functions
• Albumin-binding extensions for longer half-life
• bispecific Fc domains for dual targeting

Affinity Maturation

• Antibodies are engineered for high-affinity binding to pathological tau species
• Selectivity for phosphorylated tau (p-tau) over normal tau
• Species cross-reactivity for preclinical models

Clinical Trial Outcomes by Mechanism

| Drug | Epitope | IgG | Mechanism | Trial | Outcome |
|------|---------|-----|-----------|-------|---------|
| Gosuranemab | N-term | IgG1 | Extracellular | TANGO | Failed |
| Tilavonemab | N-term | IgG1 | Extracellular | Phase II | Failed |
| Zagotenemab | MC1 | IgG1 | Conformational | Phase II | Failed |
| Semorinemab | N-term | IgG4 | Extracellular | TAURIEL/LAURIET | Mixed |
| Bepranemab | MTBR | IgG4 | Extracellular | Phase II | 58% tau-PET reduction |
| E2814 | MTBR | IgG1 | TRIM21 | Phase III | 30-70% MTBR-tau reduction |
| PRX005 | MTBR | IgG1 | TRIM21 | Phase I | Ongoing |

Summary: Mechanism-Driven Development

The evolution of anti-tau immunotherapy reflects mechanistic learning:

The Cell 2025 review emphasizes that IgG1 MTBR-targeting antibodies represent the most promising approach, with E2814 in Phase III leading the field[@tanglederivative2024].

Blood-Brain Barrier Penetration

A critical challenge for tau immunotherapy is achieving sufficient antibody concentrations in the brain[@antibodyDelivery2021].

BBB Physiology

The blood-brain barrier presents a significant obstacle to antibody delivery:

• Tight Junctions: Endothelial cells form tight junctions limiting paracellular transport
• Efflux Transporters: P-glycoprotein and other transporters actively remove molecules
• Low Pinocytosis: Limited receptor-mediated transcytosis compared to other tissues

Antibody Transport Mechanisms

Anti-tau antibodies can cross the BBB through:

• Antibodies engineered to bind transferrin receptor (TfR)
• Bispecific antibodies targeting both tau and TfR
• Example: ABBV-8E12 (tilavonemab) used this approach

• FcRn extends antibody half-life in plasma
• Does not significantly enhance brain penetration
• Primarily maintains serum antibody levels

• Charge modifications to enhance adsorption
• Affinity maturation for lower molecular weight
• Use of brain-penetrant antibody formats

Dosing Strategies

Achieving therapeutic antibody concentrations in the brain requires:

| Strategy | Approach | Brain:Serum Ratio |
|----------|----------|-------------------|
| Standard mAb | High peripheral doses | ~0.1-0.3% |
| RMT-engineered | TfR-binding engineering | ~1-2% |
| Bispecific | Tau × TfR bispecific | ~2-5% |
| Intrathecal | Direct CNS delivery | ~100% |

Pharmacokinetic Considerations

| Parameter | IgG1 | IgG4 | Clinical Relevance |
|-----------|------|------|---------------------|
| Half-life | ~21 days | ~21 days | Monthly dosing |
| CSF/Serum ratio | ~0.1-0.5% | ~0.1-0.5% | Limited brain exposure |
| Target affinity | High | High | Triggers receptor-mediated uptake |

Dose-Response Relationships

• Linear PK: At low doses, clearance is target-mediated
• Non-linear PK: At high doses, FcRn recycling dominates
• Brain exposure: Increases with dose but plateaus
• Clinical dosing: 10-60 mg/kg monthly typically used

Molecular Mechanisms of Tau Clearance

Proteasomal Degradation Pathways

Once tau-antibody complexes enter cells, multiple degradation pathways operate[@trimmediated2024]:

TRIM21-Mediated Pathway:

Lysosomal Pathways:

Autophagy-Mediated Clearance

Tau can also be cleared through autophagy pathways:

• Macroautophagy: Tau inclusions engulfed by autophagosomes
• Chaperone-mediated autophagy (CMA): Specific tau sequences recognized
• Microglial autophagy: Enhanced in activated microglia

TRIM21 Mechanism Deep Dive

TRIM21 (Tripartite Motif-Containing Protein 21) is a cytosolic antibody receptor that mediates a powerful intracellular clearance mechanism[@trimmediated2024].

Molecular Mechanism

• Receptor-mediated endocytosis (FcR)
• Fluid-phase pinocytosis
• Direct membrane penetration (in some cases)

• TRIM21 binds Fc region with high affinity
• Forms antibody-TRIM21-tau ternary complex

• Attaches polyubiquitin chains to the complex
• K63-linked chains signal for proteasomal degradation
• Targets are directed to the 26S proteasome

• Efficient removal of intracellular tau
• Antigen presentation not triggered (non-lysosomal)

TRIM21 Expression Patterns

• Neurons: High expression in cortical and hippocampal neurons
• Glia: Moderate expression in microglia and astrocytes
• Peripheral: Low expression — limits peripheral side effects

IgG1 vs IgG4 in TRIM21 Clearance

| Property | IgG1 | IgG4 | Implication |
|----------|------|------|--------------|
| FcR affinity | High | Low | IgG1 more efficiently taken up by cells |
| TRIM21 binding | Strong | Weak | IgG1 better for intracellular clearance |
| Complement activation | Yes | No | IgG1 can engage complement cascade |
| Half-life | ~21 days | ~21 days | Similar exposure |

Clinical Correlation: E2814 (IgG1) shows greater tau reduction than semorinemab (IgG4) in clinical trials, supporting the TRIM21 mechanism hypothesis.

Fc Receptor Biology in the Brain

Microglial Fc Gamma Receptors

Microglia express multiple Fc receptor types[@tau]:

| Receptor | Affinity | Function |
|----------|----------|----------|
| FcγRI | High | Activating, strong phagocytosis |
| FcγRIIA | Medium | Activating, ITAM signaling |
| FcγRIIB | Medium | Inhibitory, ITIM signaling |
| FcγRIIIA | Variable | ADCC, phagocytosis |

Signaling Pathways

FcR engagement triggers:

• Syk kinase activation
• PI3K signaling
• Phagocytosis initiation

• SHIP1 recruitment
• Inhibits over-activation
• Prevents excessive inflammation

Microglial Activation States

• Resting: Baseline surveillance — low phagocytic activity
• Activated: Pro-inflammatory — enhanced phagocytosis
• Disease-associated: DAM/LAM states — altered function

Comparative Efficacy Analysis

Clinical Outcomes by Mechanism

The field has learned crucial lessons from head-to-head comparisons:

| Mechanism | Example | Tau PET Signal | Clinical Outcome |
|-----------|---------|----------------|------------------|
| N-term, IgG1 | Gosuranemab | Minimal change | Failed |
| N-term, IgG1 | Tilavonemab | Minimal change | Failed |
| N-term, IgG4 | Semorinemab | Modest change | Mixed |
| MTBR, IgG4 | Bepranemab | 58% reduction | Promising |
| MTBR, IgG1 | E2814 | 30-70% reduction | Phase III |
| MTBR, IgG1 | PRX005 | Ongoing | Phase I |

Mechanistic Explanations

Why N-terminal antibodies failed:

• N-terminal tau is released early but represents a small fraction of total pathology
• Antibodies cannot access intracellular tau or tangles
• Disease progression often too advanced when treatment starts

• MTBR is the core aggregation domain
• Antibodies can bind tau within filaments
• Target both extracellular and filament-associated tau

Challenges in Anti-Tau Immunotherapy

Biological Challenges

Delivery Challenges

Clinical Trial Challenges

Future Directions

Next-Generation Approaches

• Simultaneous targeting of N-term, MTBR, and C-term
• Broader epitope coverage

• Extended half-life
• Enhanced brain penetration via RMT

• Tau-targeting molecule linked to E3 ligase
• Intracellular degradation

• Anti-tau antibody + ASO
• Anti-tau + anti-amyloid
• Immunotherapy + small molecule

Biomarker Development

Future trials will increasingly use biomarker-driven patient selection:

• CSF p-tau217/p-tau181: Pre-treatment levels predict response
• Tau PET regional burden: Early-stage patients may benefit most
• Microglial activation markers: PET imaging of neuroinflammation

Combination Therapy Approaches

Rationale for Combinations

Different mechanisms may provide synergistic benefits:

| Combination | Rationale | Status |
|-------------|-----------|--------|
| Anti-tau + Anti-amyloid | Target both pathologies | Clinical trials planned |
| N-terminal + MTBR | Different epitope coverage | Preclinical |
| Antibody + ASO | Extracellular + intracellular | Preclinical |
| Antibody + OGA inhibitor | Clearance + upstream mechanism | Preclinical |

Anti-Amyloid/Anti-Tau Combination

Lecanemab (anti-amyloid) + E2814 (anti-tau) represents a comprehensive approach:

• Amyloid first: Remove existing amyloid plaques
• Tau protection: Prevent tau spread after amyloid removal
• Eisai strategy: Develop both antibodies as combo therapy

Emerging Technologies

Next-Generation Antibody Formats

• Target both tau and brain uptake receptors
• Example: TfR-tau bispecifics

• Smaller size may improve brain penetration
• scFv, Fab fragments in development

• Enhanced effector functions
• Reduced immunogenicity

Novel Delivery Approaches

Conclusion

Tau immunotherapy has evolved substantially based on mechanistic understanding:

The most advanced programs (E2814, Bepranemab) incorporate these mechanistic insights, and the field continues to refine approaches based on clinical and preclinical data.

References